Combined immunodeficiency caused by a novel homozygous NFKB1 mutation - 04/02/21
Abstract |
Background |
Genetic faults in several components of the nuclear factor-κB pathway cause immunodeficiency. Most defects lead to combined immunodeficiency with a range of severity. Heterozygous mutations in NFKB1 were associated with common variable immunodeficiency, however, homozygous mutations have not been described.
Objective |
We studied the molecular basis of combined immunodeficiency in a patient who presented with failure to thrive, persistent EBV viremia and hepatitis, pneumocystis jirovecii pneumonitis, and generalized lymphadenopathy.
Methods |
Whole genome and exome sequencing followed by Sanger confirmation were performed to identify the genetic defect. Molecular and cellular techniques were used to assess the variant impact on the nuclear factor-κB pathway and lymphocyte function.
Results |
Genetic analysis revealed a novel homozygous mutation in NFKB1, c.2878G>A, p.Gly960Arg (G960R). This affected p105 phosphorylation and p50 formation on antigen and cytokine stimulation, as well as attenuating nuclear signal transmission. As a result, both T- and B-cell maturation and function were perturbed. The number of memory CD4+ T cells were reduced, while CD8+ T cells consisted predominately of expanded differentiated populations. The function of T cells were diminished as shown by reduced responses to mitogens as well as diminished cytokine secretion. B-cell maturation was also affected, with decreased IgD+CD27+ memory B cells while transitional B cells were increased, likely contributing to the reduced ability to produce specific antibodies.
Conclusion |
Homozygous G960R mutation in NFKB1 leads to a severe clinical presentation of combined immunodeficiency. This was associated with blockade of nuclear factor-κB pathway signaling, resulting in aberrations in T- and B-cell maturation and function.
Le texte complet de cet article est disponible en PDF.Key words : NFKB1, common variable immunodeficiency, combined immunodeficiency, hypogammaglobulinemia, autoimmunity, B-cell repertoire
Abbreviations used : NF-κB, RelA
Plan
This work was supported by Immunodeficiency Canada’s Distinguished Professorship in Immunology (C.M.R.), the Program for Immunogenomics and the Canadian Centre for Primary Immunodeficiency (C.M.R.), and the Jeffrey Modell Foundation and Immunodeficiency Canada (C.M.R.). |
|
Disclosure of potential conflict of interest: D. Merico is a full-time employee of Deep Genomics and is entitled to a stock option. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 2
P. 727 - février 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?